Komori
Governance4552JCR Pharmaceuticals Co.,Ltd.Pharmaceuticals

Matters concerning the controlling shareholder and other affiliated companies

MEDIPAL HOLDINGS CORPORATION was disclosed as an “Other Affiliated Company,” together with its voting rights ratio, relationship with the Company, and concurrent officer appointments. The Company explained that it conducts its business activities and makes management decisions independently, thereby maintaining its independence.

Worth reading
44Recurring
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
23.86
Voting rights ownership ratio (%)
Wording
Conditional
How definitive the wording is.

Governance structure

Controlling shareholder
MEDIPAL HOLDINGS CORPORATION23.86%Voting rights

Other Affiliated Company, Prime Market of the Tokyo Stock Exchange), voting rights ratio: 23.86% (direct ownership: 23.86%; portion included in aggregate: —

When one company holds most of the voting rights, its wishes are more likely to prevail in management. How the interests of minority shareholders are protected is a key issue.

Changes this time

Disclosure of matters concerning the controlling shareholder, etc. (Other Affiliated Company). No changes from the previous report were stated.

Governance structure
ItemDetails
Controlling shareholderMEDIPAL HOLDINGS CORPORATION (Other Affiliated Company, Prime Market of the Tokyo Stock Exchange), voting rights ratio: 23.86% (direct ownership: 23.86%; portion included in aggregate: —)
Changes this timeDisclosure of matters concerning the controlling shareholder, etc. (Other Affiliated Company). No changes from the previous report were stated.
Items this document does not state (6)
Corporate Governance StructureNumber of directorsNumber of independent officersCommitteePolicy on cross-shareholdingsTakeover defenses

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The companies have entered into a business and capital alliance, as well as multiple commercialization, licensing and joint development agreements, to leverage the MEDIPAL Group’s logistics and sales capabilities and the Company’s drug discovery capabilities, thereby enhancing both companies’ corporate value and achieving sustainable growth.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Matters concerning the controlling shareholder and other affiliated companies | JCR Pharmaceuticals Co.,Ltd. (4552) timely disclosure | Komori